Rose McNulty

A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.

The findings suggest there are ongoing disparities between Black and White patients with hepatocellular carcinoma (HCC) in terms of both outcomes and health care resource utilization.

Interview with Al B. Benson III, MD, FACP, FACCC, FASCO, professor of medicine at Northwestern University Feinberg School of Medicine.

Michael Morse, MD, FACP, MHS, professor of medicine at Duke University School of Medicine and medical oncologist at Duke Cancer Center, discusses the etiologies of hepatocellular carcinoma (HCC) and how clinicians can tailor treatment for patients with varied levels of liver function.

A recent study suggests treatment with glucocorticoids after loss of ambulation can preserve late-stage functional abilities, respiratory function, and cardiac function in patients with Duchenne muscular dystrophy (DMD).

A new study suggests routine gastrointestinal (GI) endoscopy is not needed for most patients with mucinous ovarian cancer in the perioperative setting due to a lack of statistically significant overall survival benefits.

The new playbook details voluntary best practices for value-based care (VBC) payment arrangements and is part of an effort to increase VBC adoption in the private sector.

Michael Morse, MD, FACP, MHS, professor of medicine at Duke University School of Medicine and medical oncologist at Duke Cancer Center, spoke to the evolution of hepatocellular carcinoma (HCC) treatment in recent years, as well as ongoing research with potential to impact clinical practice.

Researchers developed a web server that can help predict therapeutic responses to combination lenvatinib and immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma (HCC).

A recent study suggests a modified model incorporating diffusion-weighted MRI can more accurately predict ovarian cancer primary debulking surgery outcomes compared with the standard, widely used Memorial Sloan Kettering Cancer Center risk model.

Julie Patterson, PharmD, PhD, senior director of research at the National Pharmaceutical Council, discussed potential impact of the Inflation Reduction Act of 2022 (IRA) on small molecule drug research and development investments toward subsequent indications.

An abstract presented at the 2024 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer explored patient-reported health-related quality of life (HRQOL) among patients treated with mirvetuximab soravtansine compared with standard chemotherapy.

Medicare’s upcoming health equity adjustment in the Hospital Value-Based Purchasing (HVBP) program will reduce disproportionate penalization among safety net hospitals and those serving high proportions of Black patients, according to a recent study.

The FDA issued complete response letters (CRLs) for the biologics license application for odronextamab in relapsed/refractory (R/R) follicular lymphoma and in R/R diffuse large B-cell lymphoma (DLBCL).

The approval, which marks the first for a once-daily, single-tablet combination therapy for pulmonary arterial hypertension, is based on findings from the phase 3 A DUE study.

Machine learning models have potential for early identification of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) who are at risk of hepatocellular carcinoma.

Mirvetuximab soravtansine-gynx (Elahere) received full FDA approval for the treatment of folate receptor alpha–positive (FRα+), platinum-resistant ovarian cancer (PROC) based on findings from the confirmatory phase 3 MIRASOL trial.

Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.

The FDA has granted accelerated approval to ponatinib (Iclusig) plus chemotherapy for the first-line treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

Padma Sripada, MD, board-certified internist, discusses the strategies she employs to consistently provide high-quality care for patients at her practice amid well-documented workforce shortages in primary care.

A recent study found significant variation in the use of recommended laboratory tests ahead of immunomodulatory treatment in patients with chronic inflammatory skin diseases, with less than 60% of patients in the US receiving recommended pretreatment testing.

A recent study found that certain gene variants may be prognostic for residual disease following resection in patients with ovarian cancer.

An analysis of nationwide data over 2 decades identified demographic-specific trends in liver cancer incidence and mortality in the US.

A novel model for gauging nutritional risk among patients with hepatocellular carcinoma (HCC) showed high accuracy and may provide a simpler, more targeted alternative to currently used nutritional risk models used for patients with cancer.

Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, discusses how closed-loop artificial pancreas systems can help reduce the burden of type 1 diabetes (T1D) management during pregnancy.

The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.

A recent study found that tumor-stroma proportion was a reliable marker of chemoresistance, progression-free survival, and overall survival in high-grade serous ovarian cancer.

Current treatment guidelines recommend using cancer antigen-125 (CA-125) as a diagnostic marker for ovarian cancer recurrence, but a recent study suggests CA-125 has poor concordance with progressive disease based on RECIST criteria.

Leslie Busby, MD, chairman of the US Oncology Network Pharmacy & Therapeutics Committee, discusses the process of developing patient-centered care plans within the framework of an accountable care organization (ACO) and the importance of staying up to date with the latest best practices and therapies.